Study links age, insurance, but not race, to chemo rates

August 10, 2012
Study links age, insurance, but not race, to chemo rates
For women with breast cancer, disease characteristics correlate significantly with chemotherapy receipt, with no indication of racial barriers to treatment, according to a study published online Aug. 6 in the Journal of Clinical Oncology.

(HealthDay) -- For women with breast cancer, disease characteristics correlate significantly with chemotherapy receipt, with no indication of racial barriers to treatment, according to a study published online Aug. 6 in the Journal of Clinical Oncology.

To examine disparities in receipt of adjuvant chemotherapy, Jennifer J. Griggs, M.D., M.P.H., from the University of Michigan in Ann Arbor, and colleagues recruited women diagnosed with and identified through the Detroit, Michigan, or Los Angeles County Surveillance, Epidemiology, and End Results registry to complete a survey.

The researchers found that, for the 1,403 women included in the analytic sample, disease characteristics correlated significantly with receipt of chemotherapy in multivariable models. Low-acculturated Hispanics and high-acculturated Hispanics were more likely to receive chemotherapy than non-Hispanic whites (odds ratio [OR], 2.00 and 1.43, respectively). Black women were less likely than non-Hispanic whites to receive chemotherapy, but the difference was not significant (OR, 0.83; 95 percent confidence interval, 0.64 to 1.08). Even in women younger than 50 years of age, increasing age correlated with lower rates of chemotherapy receipt, as did Medicaid insurance.

"In conclusion, it seems that race and ethnicity need not pose barriers to receipt of ," the authors write. "Such a finding is encouraging as we continue to address racial and in the receipt of quality cancer care. Nonetheless, differences and disparities do exist in receipt of chemotherapy according to age, insurance, and employment status."

Explore further: Gene expression profile testing increasing in breast cancer

More information: Abstract
Full Text (subscription or payment may be required)
Editorial

Related Stories

Gene expression profile testing increasing in breast cancer

May 18, 2012
(HealthDay) -- From 2006 to 2008, the use of gene expression profile (GEP) testing increased, correlating with a decrease in the percentage of women with hormone receptor (HR)-positive breast cancer receiving adjuvant chemotherapy, ...

Even with insurance, racial disparities in breast cancer treatment persist

July 27, 2012
More White women are diagnosed with breast cancer than Black women, yet Black women with breast cancer have a higher mortality rate. One potential explanation for this disparity is delayed treatment, perhaps due to differences ...

Recommended for you

Researchers develop test that can diagnose two cancer types

December 12, 2017
A blood test using infrared spectroscopy can be used to diagnose two types of cancer, lymphoma and melanoma, according to a study led by Georgia State University.

Atoh1, a potential Achilles' heel of Sonic Hedgehog medulloblastoma

December 12, 2017
Medulloblastoma is the most common type of solid brain tumor in children. Current treatments offer limited success and may leave patients with severe neurological side effects, including psychiatric disorders, growth retardation ...

Cancer-causing mutation suppresses immune system around tumours

December 12, 2017
Mutations in 'Ras' genes, which drive 25% of human cancers by causing tumour cells to grow, multiply and spread, can also protect cancer cells from the immune system, finds a new study from the Francis Crick Institute and ...

Drug suppresses spread of breast cancer caused by stem-like cells

December 12, 2017
Rare stem-like tumor cells play a critical role in the spread of breast cancer, but a vulnerability in the pathway that powers them offers a strategy to target these cells using existing drugs before metastatic disease occurs, ...

MRI scans predict patients' ability to fight the spread of cancer

December 12, 2017
A simple, non-invasive procedure that can indicate how long patients with cancer that has spread to the brain might survive and whether they are likely to respond to immunotherapy has been developed by researchers in Liverpool.

A new weapon against bone metastasis? Team develops antibody to fight cancer

December 11, 2017
In the ongoing battle between cancer and modern medicine, some therapeutic agents, while effective, can bring undesirable or even dangerous side effects. "Chemo saves lives and improves survival, but it could work much better ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.